Special Issue

Towards Personalized Medicine in Breast Cancer

Message from the Guest Editor

Breast cancer is one of the most prevalent cancers among women and is recognized as a highly heterogeneous disease. Despite significant progress in early detection and treatment, challenges such as recurrence, metastasis, and drug resistance remain major obstacles. Advances in genomics, molecular biology, and bioinformatics have revolutionized the field, enabling personalized approaches to breast cancer management through tailored diagnostic tools and therapies. This Special Issue of the Journal of Personalized Medicine invites high-quality contributions exploring personalized approaches across the spectrum of breast cancer care, including prevention, early detection, diagnosis, treatment, and survivorship. Topics of interest include innovative immunotherapies. targeted treatments, surgical advancements, resistance mechanisms, and translational research to improve patient outcomes. Studies addressing clinical. molecular, and bioinformatic perspectives are particularly welcome.

Guest Editor

Dr. Eun Young Kim

Department of Surgery, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul 03181, Republic of Korea

Deadline for manuscript submissions

closed (31 October 2025)



Journal of Personalized Medicine

an Open Access Journal by MDPI

CiteScore 6.0
Indexed in PubMed



mdpi.com/si/230196

Journal of Personalized Medicine Editorial Office MDPI, Grosspeteranlage 5 4052 Basel, Switzerland Tel: +41 61 683 77 34 jpm@mdpi.com

mdpi.com/journal/ jpm





Journal of Personalized Medicine

an Open Access Journal by MDPI

CiteScore 6.0 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine is one of the few journals that covers the diverse areas involved in the field, including research at basic, translational, and clinical levels. It focuses on "omics"-level studies that seek to define the basis of interindividual variation in susceptibility for a disease, its prognosis or definition of clinical

subsets, and response to therapy (pharmacogenomics). We are also interested in systems biology as it relates to interindividual variation, and research on new methodologies, informatics, and biostatistics, in the aforementioned areas.

Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker

Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W.F, Toronto, ON M5S 3H2. Canada

Author Benefits

High Visibility:

indexed within Scopus, PubMed, PMC, Embase, and other databases.

Journal Rank:

CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21.5 days after submission; acceptance to publication is undertaken in 3.5 days (median values for papers published in this journal in the first half of 2025).

